Drug Discovery

Shenogen enters into an exclusive license with BioArdis to develop and commercialise FGFR4 kinase inhibitor for Asian market

Shenogen has entered into an exclusive collaboration and licensing agreement with Shanghai BioArdis and BioArdis for the development and commercialization of BioArdis' novel FGFR4 (fibroblast growth factor receptor 4) kinase inhibitor, BIO-1262/SNG-203, either as monotherapy or combination therapy in Mainland China, Hong Kong, Macau and Taiwan.

Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19

Vir Biotechnology and Alnylam Pharmaceuticals, Inc. announced an expansion to their broad multi-target existing collaboration for the development and commercialization of RNAi therapeutics for infectious diseases, including SARS-CoV-2, the virus that causes the disease COVID-19.

Novartis unveils plans to begin trial with Jakavi in severe COVID-19 patients

Novartis has unveiled plans to commence a clinical trial of Jakavi (ruxolitinib) in severe COVID-19 patients and establish an international compassionate use programme.

Citius, Novellus collaborate on novel stem-cell therapy for ARDS associated with COVID-19

Citius Pharmaceuticals has entered into an exclusive six-month option agreement with Novellus subsidiary to licence novel stem-cell therapy for acute respiratory distress syndrome (ARDS) associated with COVID-19, the disease caused due to the novel coronavirus SARS-CoV-2.

Tsinghua and partners to develop neutralising antibodies against COVID-19

Tsinghua University has joined forces with 3rd People’s Hospital of Shenzhen and Brii Biosciences (Brii Bio) to develop neutralising antibodies against COVID-19 (novel coronavirus).

VBI Vaccines collaborates with the National Research Council of Canada to develop pan-coronavirus vaccine candidate

VBI Vaccines, a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced a collaboration with the National Research Council of Canada (NRC), Canada’s largest federal research and development organization, to develop a pan-coronavirus vaccine candidate, targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).

Eli Lilly, Sitryx sign potential $880m deal to develop immunometabolic medicines

Eli Lilly has entered into a potential $880m research deal with Sitryx to discover and develop new immunometabolic medicines.

Aptorum to investigate use of repurposed drug candidates for coronavirus

Aptorum Group has joined forces with Covar Pharmaceuticals for studying the use of three repurposed drug candidates for the treatment of novel coronavirus (COVID-19).

Sanofi, Translate Bio to develop novel mRNA vaccine for COVID-19 disease

Sanofi’s vaccines global business unit Sanofi Pasteur has collaborated with Translate Bio for the development of a novel messenger RNA (mRNA) vaccine for COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.